CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...
Phase 3
Baltimore, Maryland, United States and 125 other locations
The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...
Phase 3
Baltimore, Maryland, United States and 164 other locations
Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children ...
Phase 1
Baltimore, Maryland, United States and 23 other locations
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid...
Phase 3
Washington, District of Columbia, United States and 23 other locations
People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML hav...
Phase 1, Phase 2
Baltimore, Maryland, United States and 18 other locations
the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-leukemic activity of WU-NK-101 in R/R AML....
Phase 1
Baltimore, Maryland, United States and 8 other locations
The purpose of this Phase I, multicenter, clinical trial is to evaluate the safety of AG-120 and AG-221 when given in combination with standard AML...
Phase 1
Baltimore, Maryland, United States and 16 other locations
or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or i...
Phase 1, Phase 2
Baltimore, Maryland, United States and 36 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomiz...
Phase 2
Baltimore, Maryland, United States and 43 other locations
This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1...
Phase 1, Phase 2
Washington, District of Columbia, United States and 2 other locations
Clinical trials
Research sites
Resources
Legal